Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma.
The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice.
from MassDevice http://bit.ly/2DZ57f4
Cap comentari:
Publica un comentari a l'entrada